<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451671</url>
  </required_header>
  <id_info>
    <org_study_id>TD002</org_study_id>
    <nct_id>NCT01451671</nct_id>
  </id_info>
  <brief_title>Development of a Prenatal Test for Fetal Aneuploidy Detection</brief_title>
  <official_title>Prenatal Test for Fetal Aneuploidy Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cindy Cisneros</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roche Sequencing Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study to develop and evaluate a blood based prenatal blood test.
      Pregnant women confirmed to be carrying a fetus with a chromosomal abnormality will be
      eligible. Subjects will be asked to provide a blood sample and a limited amount of clinical
      data that will be recorded on a case report form. All samples and clinical data will be
      stripped of subject identifiers prior to submission to Ariosa.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of aneuploidy</measure>
    <time_frame>At enrollment</time_frame>
  </primary_outcome>
  <enrollment type="Actual">1500</enrollment>
  <condition>Fetal Complications</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women carrying a fetus with an abnormal chromosomal condition that has been
        confirmed by invasive testing.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has singleton pregnancy

          -  Subject is confirmed via invasive testing to be carrying a fetus with a chromosomal
             abnormality

          -  Subject is able to provide informed consent

          -  Subject is â‰¥ 18 years of age

        Exclusion Criteria:

          -  Subject is pregnant with more than one fetus

          -  Subject (mother) has a known aneuploidy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracy Roberts</last_name>
    <role>Study Director</role>
    <affiliation>Ariosa Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Healthcare</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Roche Sequencing Solutions</investigator_affiliation>
    <investigator_full_name>Cindy Cisneros</investigator_full_name>
    <investigator_title>CRA</investigator_title>
  </responsible_party>
  <keyword>fetal</keyword>
  <keyword>aneuploidy</keyword>
  <keyword>non-invasive</keyword>
  <keyword>prenatal</keyword>
  <keyword>cell free DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneuploidy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

